SequelSEC

BIO-TECHNE Corp TECH

Biological Products, (No Diagnostic Substances) · CIK 0000842023 · Fiscal year ends 0630

Revenue
$1.22B
Fiscal year ended 2026-06-30
Operating income
$251.89M
Fiscal year ended 2026-06-30
Free cash flow
$263.22M
Fiscal year ended 2026-06-30

BIO-TECHNE Corp (TECH) reported revenue of $1.22B for the fiscal year ended 2026-06-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from BIO-TECHNE Corp’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).

Income

BIO-TECHNE Corp income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302025-06-302024-06-302023-06-302022-06-302021-06-302020-06-302019-06-302018-06-302017-06-30
Revenue$1.22B$1.22B$1.16B$1.14B$1.11B$931.03M$738.69M$714.01M$642.99M$563.00M
Cost of revenue$415.97M$429.36M$389.34M$366.89M$349.10M$298.18M$255.50M$240.52M$210.85M$188.46M
Gross profit$799.07M$790.27M$769.72M$769.82M$756.50M$632.85M$483.19M$473.49M$432.14M$374.54M
Operating income$251.89M$102.26M$206.69M$298.94M$296.59M$237.30M$157.42M$146.72M$136.18M$120.58M
Net incomeUnavailable$73.40M$168.10M$285.26M$272.05M$140.41M$229.30M$96.07M$126.15M$76.09M
Research & developmentUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Weighted-average diluted sharesshares 157.01Mshares 159.72Mshares 160.77Mshares 161.86Mshares 164.11Mshares 161.93Mshares 39.40Mshares 38.89Mshares 38.06Mshares 37.50M
Pretax income$240.68M$98.46M$185.69M$338.66M$301.39M$148.18M$276.48M$112.02M$125.95M$111.96M
Income tax expense$58.82M$25.06M$17.58M$53.22M$38.29M$8.59M$47.18M$15.94M-$198.00K$35.88M
Diluted EPS$1.16$0.46$1.05$1.76$1.66$0.87$5.82$2.47$3.31$2.03
Selling, general & administrative$452.42M$588.52M$466.38M$378.38M$372.77M$324.95M$260.58M$264.36M$240.64M$200.44M
General & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

BIO-TECHNE Corp balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302025-06-302024-06-302023-06-302022-06-302021-06-302020-06-302019-06-302018-06-302017-06-30
Cash & equivalents$264.71M$162.19M$151.79M$180.57M$172.57M$199.09M$146.62M$100.89M$121.99M$91.61M
Total assets$2.59B$2.56B$2.70B$2.64B$2.29B$2.26B$2.03B$1.88B$1.59B$1.56B
Current assets$744.40M$608.30M$617.42M$621.48M$605.56M$510.61M$520.92M$412.61M$398.37M$348.02M
Total liabilitiesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current liabilities$163.70M$175.85M$159.38M$128.51M$176.02M$152.28M$106.67M$101.98M$79.51M$135.52M
Total equity incl. NCI$2.11B$1.92B$2.07B$1.97B$1.70B$1.57B$1.38B$1.17B$1.08B$949.63M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Inventory$195.74M$189.45M$179.73M$171.64M$141.12M$116.75M$103.15M$91.05M$85.65M$85.65M
Accounts receivable$216.58M$206.88M$241.39M$218.47M$194.55M$145.38M$122.53M$137.47M$120.30M$116.83M
Goodwill$975.36M$980.94M$972.66M$872.74M$822.10M$843.07M$728.31M$732.67M$597.89M$579.03M
Long-term debt$200.00M$346.00M$319.00M$350.00M$243.41M$328.83M$344.24M$492.66M$339.00M$343.77M
Accounts payable$26.70M$25.31M$37.97M$25.68M$33.86M$29.38M$23.09M$16.21M$18.45M$16.86M

Cash flow

BIO-TECHNE Corp cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302025-06-302024-06-302023-06-302022-06-302021-06-302020-06-302019-06-302018-06-302017-06-30
Operating cash flow$292.07M$287.56M$298.98M$254.39M$325.27M$352.16M$205.22M$181.62M$170.37M$143.72M
Capital expenditures$28.85M$31.01M$62.88M$38.24M$44.91M$44.30M$51.74M$25.41M$20.93M$15.18M
Investing cash flow-$18.19M-$35.18M-$203.03M-$265.65M-$96.85M-$243.52M$27.10M-$336.80M-$38.71M-$305.95M
Financing cash flow-$169.11M-$253.90M-$122.40M$22.62M-$242.85M-$62.55M-$183.80M$134.38M-$99.19M$189.11M
Net change in cash$102.53M$10.40M-$28.78M$8.00M-$26.52M$52.47M$45.74M-$21.10M$30.38M$27.38M
Stock-based compensation$41.36M$40.83M$38.04M$39.23M$42.18M$48.98M$32.37M$32.28M$28.24M$14.63M
Common dividends paid$49.92M$50.39M$50.42M$50.28M$50.18M$49.62M$48.90M$48.36M$47.97M$47.32M
Common share repurchases$41.68M$275.73M$80.04M$19.56M$160.95M$43.18M$50.11M$15.40M$0Unavailable
Depreciation & amortization$97.36M$109.90M$111.71M$107.24M$101.07M$87.75M$82.74M$78.17M$64.46M$60.04M

Derived

BIO-TECHNE Corp derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302025-06-302024-06-302023-06-302022-06-302021-06-302020-06-302019-06-302018-06-302017-06-30
Free cash flow$263.22M$256.55M$236.10M$216.15M$280.36M$307.86M$153.47M$156.21M$149.43M$128.54M
Gross margin65.8%64.8%66.4%67.7%68.4%68.0%65.4%66.3%67.2%66.5%
Operating margin20.7%8.4%17.8%26.3%26.8%25.5%21.3%20.5%21.2%21.4%
FCF margin21.7%21.0%20.4%19.0%25.4%33.1%20.8%21.9%23.2%22.8%
SBC / revenue3.4%3.3%3.3%3.5%3.8%5.3%4.4%4.5%4.4%2.6%
Current ratio4.55x3.46x3.87x4.84x3.44x3.35x4.88x4.05x5.01x2.57x
Revenue YoY growth-0.4%5.2%2.0%2.8%18.7%26.0%3.5%11.0%14.2%Unavailable
Net marginUnavailableUnavailableUnavailable25.1%24.6%15.1%31.0%13.5%19.6%13.5%
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenue2.4%2.5%5.4%3.4%4.1%4.8%7.0%3.6%3.3%2.7%
Long-term debt / equity0.09x0.18xUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rate24.4%25.5%9.5%15.7%12.7%5.8%17.1%14.2%-0.2%32.0%

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open TECH in the interactive workspace to inspect any figure back to its filing.

Source filings

10-K · Filed 2026-08-24View SEC filing
10-Q · Filed 2026-05-06View SEC filing
10-Q · Filed 2026-02-04View SEC filing
10-Q · Filed 2025-11-05View SEC filing
10-K · Filed 2025-08-22View SEC filing
10-Q · Filed 2025-05-08View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.